One of the major problems with the diagnosis and treatment of neurological diseases is the inability of clinicians to determine the onset of disease. T he present invention describes methods and kits whereby the onset of neuropathology is detected by changes in the normal levels of neurosteroids, and particularly DHEA and its metabolic precursors, in the brain and serum.< /SDOAB>
NEUROSTEROIDS AS MARKERS FOR ALZHEIMER'S DISEASE